Tazeen Ahmad

Reshma: engineered TACI, continuous (no on/off cycling) dosing, and once-monthly auto-injector should beat rivals across efficacy, safety, admin.

Reshma confirmed VX-828 readout will include sweat chloride and safety from a small patient cohort. Not powered for ppFEV1.

Reshma cited IgAN PK, PD, proteinuria, and safety data as positive signals for membranous, though noting the autoantibody target differs (PLA2R vs GdIgA1).

Reshma pointed to RUBY-3 80mg IgAN cohort as best analog for RAINIER, citing 56% proteinuria reduction at 36 weeks. Emphasized compounding benefit over decades of chronic treatment where even small proteinuria improvements matter.

Reshma confirmed a pre-BLA meeting was completed where FDA reviewed all data and filing plans, leading to breakthrough designation and rolling submission endorsement based on unmet need and attractive clinical profile.

Reshma confirmed auto-injector launch for IgAN. On gMG prioritization, cited high unmet need, strong emerging class data, efficient regulatory pathway, and pove's engineered best-in-class properties.

Duncan detailed usage across surgery and non-surgery settings, from joint replacements to ankle sprains and fractures. Also seeing repeat physician use with positive clinical feedback.

Reshma detailed VX-880 targeting ~60,000 patients initially, with encapsulated device program and hypoimmune gene-edit programs aimed at all T1D patients.

Stuart confirmed expectation of transitions from TRIKAFTA and older modulators to ALYFTREK but declined to give switching rate guidance.

Tolga addressed both the channel split and the education gap, and Pushkal added the HELIOS-B and APOLLO-B evidence for additive benefit on top of stabilizers.

R&D head expressed confidence competitor results would be positive and validate class effect already demonstrated in HELIOS-B. Positioned nucresiran TRITON-CM as potentially the largest combination dataset.

Management expects nuceresiran to drive swift uptake post-2030 with best-in-class profile and no royalty obligations, potentially pushing operating margins to mid-40s. CFO noted consensus gross margins mid-70s through 2030, with vast majority of compression from Sanofi royalty.

Management confirmed no payer headwinds across all segments. 2026 policies being negotiated with similar favorable dynamics expected. No step edit expansion anticipated.

CFO confirmed mid-single-digit net price reduction for AMVUTTRA in 2025 vs 2024. Payer dynamics moving as expected with first-line access and minimal out-of-pocket costs.

Management confirmed broad prescriber mix with both existing PN prescribers and new cardiologists adopting AMVUTTRA for CM, highlighting rapid formulary adoption as key enabler.

Management directly addressed timeline, stating payer policy and formulary uptake will take months post-approval with meaningful demand ramping in H2 2025.

Cagnoni described the existing subcutaneous path as clear with an FDA bridging strategy, and positioned Halozyme as added optionality unrelated to emerging data.

Bill sees oral approvals medicalizing vitiligo like AD/psoriasis. Incyte has topical-to-oral advantage with Opzelura for BSA<10 and povo for BSA>10. Mohamed sized systemic vitiligo TAM at $1.5-2B.

Bill broke down: AD 60% of business growing ~20%, vitiligo 40% growing mid-teens. Pediatric annualizing $30M. International doubling to $130M. 10-15% CAGR over next 5 years with organic + HS indication + EU AD launch driving toward ~$1.3B by 2030.

Pablo confirmed 50 monotherapy patients with substantial follow-up. Benchmarked against momelotinib (SVR35 7-22%, TSS50 25-26%). Will include clinical endpoints plus translational disease-modification data.

Pablo emphasized mechanistic clarity from ET increases MF confidence. Shifted MF data release to later in year to include combination data with ruxolitinib. Expects spleen volume reduction, symptom improvement, hemoglobin improvement.

Pablo confirmed substantive CALR data coming in 2025 with dose escalation across ET and MF, including clinical endpoints and early VAF variability/fraction burden data.

Christiana broke down guidance drivers: continued AD/vitiligo growth, pediatric launch contribution, European expansion. Noted tube usage evolving with patient activation.

Berger confirmed a Phase 2 update for the Alpha 4 Beta 7 IBD program later this year, with clinical and histological remission endpoints.

Joanna emphasized Trodelvy's established standard-of-care position and NCCN category 1 recognition but did not directly address the competitive impact from datopotamab's potential approval.

Johanna expects both Descovy and YES2GO to grow in 2026 with rising awareness lifting all boats. YES2GO will become market leader over time. Descovy growth expected to erode as YES2GO gains share. Declined to discuss gross-to-net specifics but noted YES2GO value proposition is recognized in 90% access achievement.

All three of McCourt, Schleifer and Yancopoulos answered, contrasting quarterly dosing and sustained efficacy against FcRn cycling and loss of response over time.

Schleifer pushed back on the premise, noting Regeneron has nearly 50 pipeline programs and doesn't focus narrowly on simple DUPIXENT replacement.

Yancopoulos argued antibodies and siRNAs are more powerful than aptamers/peptides used in approved GA therapies. Systemic approach avoids bilateral injection burden and blinding risks (retinal vasculitis). Testing both cemdisiran monotherapy and combo. Crowe confirmed prospective secondary endpoint for 15-letter visual acuity loss.